Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2005 2
2009 2
2012 1
2014 1
2015 1
2017 2
2018 3
2019 3
2020 3
2021 4
2022 6
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Targeting CD47 for cancer immunotherapy.
Jiang Z, Sun H, Yu J, Tian W, Song Y. Jiang Z, et al. Among authors: tian w. J Hematol Oncol. 2021 Oct 30;14(1):180. doi: 10.1186/s13045-021-01197-w. J Hematol Oncol. 2021. PMID: 34717705 Free PMC article. Review.
Proximity-inducing modalities: the past, present, and future.
Singh S, Tian W, Severance ZC, Chaudhary SK, Anokhina V, Mondal B, Pergu R, Singh P, Dhawa U, Singha S, Choudhary A. Singh S, et al. Among authors: tian w. Chem Soc Rev. 2023 Aug 14;52(16):5485-5515. doi: 10.1039/d2cs00943a. Chem Soc Rev. 2023. PMID: 37477631 Review.
SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the "don't eat me" signal and activating the "eat me" signal.
Yu J, Li S, Chen D, Liu D, Guo H, Yang C, Zhang W, Zhang L, Zhao G, Tu X, Peng L, Liu S, Bai X, Song Y, Jiang Z, Zhang R, Tian W. Yu J, et al. Among authors: tian w. J Hematol Oncol. 2022 Nov 16;15(1):167. doi: 10.1186/s13045-022-01385-2. J Hematol Oncol. 2022. PMID: 36384978 Free PMC article.
IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy.
Li S, Chen D, Guo H, Yang Y, Liu D, Yang C, Bai X, Zhang W, Zhang L, Zhao G, Tu X, Peng L, Liu S, Song Y, Jiang Z, Zhang R, Yu J, Tian W. Li S, et al. Among authors: tian w. Antib Ther. 2023 Sep 9;6(4):240-252. doi: 10.1093/abt/tbad020. eCollection 2023 Oct. Antib Ther. 2023. PMID: 37846296 Free PMC article.
38 results